BBC NEWS Americas Africa Europe Middle East South Asia Asia Pacific Arabic Spanish Russian Chinese Welsh
BBCi CATEGORIES   TV   RADIO   COMMUNICATE   WHERE I LIVE   INDEX    SEARCH 

BBC NEWS
 You are in: Business
Front Page 
World 
UK 
UK Politics 
Business 
Market Data 
Economy 
Companies 
E-Commerce 
Your Money 
Business Basics 
Sci/Tech 
Health 
Education 
Entertainment 
Talking Point 
In Depth 
AudioVideo 


Commonwealth Games 2002

BBC Sport

BBC Weather

SERVICES 
Tuesday, 2 October, 2001, 11:03 GMT 12:03 UK
Bayer buys into agriculture
Bayer's headquarters in Leverkusen
Bayer's purchase will boost its agricultural sales as its drugs unit suffers
German drugs firm Bayer has agreed to buy the crop sciences unit of French rival Aventis for 7.25bn euros ($6.6bn; 4.5bn).

The deal, which was previously expected to be finalised in September, means synergies with existing operations of about 500m euros a year, Bayer said.

But the creation of the resulting Bayer CropScience unit is likely to cost 4,000 jobs - about 15-18% of the combined workforce.

The German company is taking on 2bn euros in debt as part of the deal, the cost of which in restructuring charges will also be about 500m euros.

Fellow German drugs firm Schering will share in the proceeds as a result of its 24% stake in the CropScience division.

Up the rankings

The purchase will see Bayer leap into the global number two spot in the agrichemicals business, more than doubling its existing turnover in the sector to about 6.5-7bn euros, the company said.

As a result, Bayer will take on the Rovral fungicide, used on fruit and vegetables, and the popular pesticide known as Regent.

There are still competition hurdles to be jumped, in both Europe and the US. Regulators are likely to want to check that the merger does not give Bayer undue control over the market for chemicals for specific crops.

Baycol troubles

Bayer has been hit hard in recent weeks by trouble in its drugs unit.

On Tuesday, it announced 1,250 job cuts at its pharmaceutical business, which has been battered by plummeting sales.

Its headline anti-cholesterol drug, Baycol/Lipobay, has been banned around the world over fears of fatal side-effects, generating a string of lawsuits.

The withdrawal of the drug, Bayer's number three pharmaceutical product, cost the company about 800m euros a year.

And the drug unit is now to be split in two, to ensure greater management focus. The two segments, covering chemical and biological products, are both looking for strategic alliances.

See also:

13 Sep 01 | Business
Bayer stresses continuity
04 Sep 01 | Business
Investigation launched into Bayer
16 Aug 01 | Business
Troubled Bayer puts off NY listing
15 Aug 01 | Business
Bayer sued over danger drug
13 Aug 01 | Business
Bayer drug linked to more deaths
10 Aug 01 | Business
Bayer to cut more than 4,000 jobs
09 Aug 01 | Business
Bayer confirms profits slump
08 Aug 01 | Business
Bayer shares plunge
27 Jun 01 | Business
Bayer warns on 2001 profits
22 Jun 01 | Business
Drug giant warns of lower profits
21 Jun 01 | Business
BASF shuts plants
21 Nov 00 | Business
Drugs - a high-risk business
Internet links:


The BBC is not responsible for the content of external internet sites

Links to more Business stories are at the foot of the page.


E-mail this story to a friend

Links to more Business stories